AI Article Synopsis
- The study aimed to analyze how quickly cannabidiol (CBD) affects seizure reduction and adverse events in patients with drug-resistant epilepsy associated with tuberous sclerosis complex.
- Patients received either CBD (25 mg/kg/day or 50 mg/kg/day) or a placebo for 16 weeks, with results showing noticeable seizure reduction starting by Day 6 and attaining statistical significance by Day 10.
- Adverse events were more frequent in CBD groups but typically resolved within the trial period, indicating that while CBD may have side effects, most patients experienced resolution of these issues over time.
Article Abstract
Objective: To estimate the timing of cannabidiol (CBD) treatment effect (seizure reduction and adverse events [AEs]) onset, we conducted a post hoc analysis of GWPCARE6 (NCT02544763), a randomized, placebo-controlled, phase 3 trial in patients with drug-resistant epilepsy associated with tuberous sclerosis complex (TSC).
Methods: Patients received plant-derived pharmaceutical formulation of highly purified CBD (Epidiolex; 100 mg/ml oral solution) at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or placebo for 16 weeks (4-week titration, 12-week maintenance). Treatment started at 5 mg/kg/day for all groups and reached 25 mg/kg/day on Day 9 and 50 mg/kg/day on Day 29. Percentage change from baseline in TSC-associated seizure (countable focal or generalized) count was calculated by cumulative day (i.e., including all previous days). Time to onset and resolution of AEs were evaluated.
Results: Of 224 patients, 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo. Median (range) age was 11.3 (1.1-56.8) years. Patients had discontinued a median (range) of 4 (0-15) antiseizure medications and were currently taking 3 (0-5). Difference in seizure reduction between CBD and placebo emerged on Day 6 (titrated dose, 15 mg/kg/day) and became nominally significant (p < .049) by Day 10. Separation between placebo and CBD in ≥50% responder rate also emerged by Day 10. Onset of AEs occurred during the first 2 weeks of the titration period in 61% of patients (CBD25, 61%; CBD50, 67%; placebo, 54%). In patients with an AE, resolution occurred within 4 weeks of onset in 42% of placebo and 27% of CBD patients and by end of trial in 78% of placebo and 51% of CBD patients.
Significance: Onset of treatment effect occurred within 6-10 days. AEs lasted longer for CBD than placebo, but the most common (diarrhea, decreased appetite, and somnolence) resolved during the 16-week trial in most patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314914 | PMC |
| http://dx.doi.org/10.1111/epi.17199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of B cells in the pathogenesis of type 1 diabetes.
Front Immunol
December 2024
Department of Immunology, School of Medicine, Yangtze University, Jingzhou, China.
Type 1 diabetes (T1D) is a metabolic disorder caused by a complete lack of insulin, primarily manifested by hyperglycemia. The mechanisms underlying the onset of T1D are complex, involving genetics, environment, and various unknown factors, leading to the infiltration of various immune components into the islets. Besides T cells, B cells are now considered important contributors to the pathogenesis of T1D, according to recent studies.
View Article and Find Full Text PDFPTCD and choledochoscopy for recurrent choledocholithiasis after multiple abdominal surgeries: a case report.
Front Med (Lausanne)
December 2024
Department of General Surgery, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, China.
Background: Special attention should be given to intra-abdominal adhesions in patients with a history of open cholecystectomy for gallstones or abdominal surgery. Choosing the appropriate surgical approach to remove the stones is crucial.
Patient Summary: A 68-year-old male was admitted due to sudden onset of upper abdominal pain lasting more than 6 h.
Monocular eye-cueing shifts eye balance in amblyopia.
J Vis
January 2025
McGill Vision Research, Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC, Canada.
Here, we investigate the shift in eye balance in response to monocular cueing in adults with amblyopia. In normally sighted adults, biasing attention toward one eye, by presenting a monocular visual stimulus to it, can shift eye balance toward the stimulated eye, as measured by binocular rivalry. We investigated whether we can modulate eye balance by directing monocular stimulation/attention in adults with clinical binocular deficits associated with amblyopia and larger eye imbalances.
View Article and Find Full Text PDFSuccessful venous thrombectomy for extensive cerebral venous and sinus thrombosis after failed diagnostic lumbar puncture.
Rofo
January 2025
Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany.
With an incidence of 2-5 per million adults, cerebral venous and sinus thrombosis (CVST) is a rarity in the spectrum of cerebrovascular diseases. The etiology and symptomatic presentation are heterogeneous and diverse. CSVT is, therefore, often underdiagnosed.
View Article and Find Full Text PDFMobile Sleep Lab: Comparison of polysomnographic parameters with a conventional sleep laboratory.
PLoS One
January 2025
International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki, Japan.
In remote areas, visiting a laboratory for sleep testing is inconvenient. We, therefore, developed a Mobile Sleep Lab in a bus powered by fuel cells with two sleep measurement chambers. As the environment in the bus could affect sleep, we examined whether sleep testing in the Mobile Sleep Lab was as feasible as in a conventional sleep laboratory (Human Sleep Lab).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!